Introduction
============

Behçet's disease (BD) is an idiopathic, chronic, relapsing, multisystemic, vasculitic inflammatory disorder presenting with triple-symptom complex of recurrent oral aphthous ulcers, genital ulcers, and uveitis. Gastrointestinal, pulmonary, musculoskeletal, cardiovascular, and neurological systems can be involved.[@b1-tcrm-11-1587],[@b2-tcrm-11-1587] BD is generally seen in East Asia and the Mediterranean rather than in Western countries. The disease affects both sexes equally and the age of onset is in the third or fourth decade of life.[@b3-tcrm-11-1587]

The etiopathogenesis of BD remains unclear because of its rarity and corresponding lack of clinical evidence, but the most credited hypothesis suggests a complex interaction among immune mechanisms, genetic factors (especially, in Turks and Japanese patients, *HLA-B51* gene may be responsible for genetic susceptibility), and environmental factors, such as microbial agents (*Saccharomyces cerevisiae*, *Mycobacteria*, *Borrelia burgdorferi*, *Helicobacter pylori*, *Escherichia coli*, *Staphylococcus aureus*, *Mycoplasma fermentans*, *Streptococcus sanguinis*, herpes simplex virus).[@b4-tcrm-11-1587]--[@b6-tcrm-11-1587] Chronicity, inflammation, and the drugs used for treatment may lead to bone loss in BD.

Chronic inflammation may cause the development of osteoporosis (OP), which is a significant skeletal disorder characterized by low bone mass. Reduced bone mineral density (BMD) and OP are major risk factors for bone fractures and are frequently observed in several rheumatological disorders such as BD, rheumatoid arthritis (RA), ankylosing spondylitis, familial Mediterranean fever (FMF), and systemic lupus erythematosus (SLE).[@b7-tcrm-11-1587]--[@b9-tcrm-11-1587] Besides the chronic inflammation, the drugs used for treatment of the various symptoms of BD such as anticonvulsants, corticosteroids, disease-modifying antirheumatic drugs, hormone replacement therapy, bisphosphonates, vitamin D, xuoride, calcitonin, and diuretics may affect bone mineral status.[@b10-tcrm-11-1587],[@b11-tcrm-11-1587] Some studies have suggested that long-term drug use may reduce BMD,[@b12-tcrm-11-1587],[@b13-tcrm-11-1587] although evidence of the real effect remains controversial.[@b10-tcrm-11-1587]

BMD is seen as an important factor in treatment planning by oral surgeons and affects the success of dentomaxillofacial operations such as bone grafting, periodontal procedures, and especially dental implants.[@b14-tcrm-11-1587]--[@b17-tcrm-11-1587] In the success of dental implant surgery, osteointegration is influenced by bone volume and quality.[@b18-tcrm-11-1587] Therefore, systemic inflammatory diseases that affect BMD become a highly significant and attractive issue for oral surgeons.

In the evaluation of BMD, dual energy X-ray absorptiometry (DXA) is a valid, noninvasive technique. Some studies have reported investigations of lumbar and femoral BMD in patients with BD.[@b3-tcrm-11-1587],[@b10-tcrm-11-1587] However, to the best of our knowledge, the effect of BD on mandibular bone density has not yet been investigated. The first aim of the present study was to evaluate mandibular BMD in BD patients with DXA. The second aim was to compare the BMD values of BD patients and healthy subjects using DXA. The third aim was to describe the effect of long-term disease duration on BMD.

Materials and methods
=====================

Patients
--------

Approval for the study was granted by the Ethics Committee of Bezmialem Vakif University Faculty of Medicine. DXA examinations were then applied in the Bone Densitometry Unit of the Department of Physical Medicine and Rehabilitation of Afyon Kocatepe University.

The study included 45 adults with BD (male/female: 24/21) and 30 volunteer healthy adults (male/female: 15/15) as a control group. All patients gave informed written consent. A questionnaire was used to collect information on age, sex, disease history, drug status, menopausal status, weight, and height. The control group was randomly chosen from patients in the Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Afyon Kocatepe University. All BD patients were receiving 1--1.5 mg/day of colchicines therapy. The patients were divided into four groups according to the disease duration: healthy controls (group 1); patients with BD between 0 and 5 years disease duration (group 2); patients with BD between 6 and 10 years disease duration (group 3); and patients with BD more than 10 years disease duration (group 4).

Exclusion criteria
------------------

Patients who had been previously diagnosed with any systemic disease other than BD or who had taken any drugs in the last 6 months which could affect BMD (including steroids, anticonvulsants, corticosteroids, disease-modifying antirheumatic drugs, hormone replacement therapy, bisphosphonates, vitamin D, xuoride, calcitonin, and diuretics) were excluded from the study.

Patients with considerable infection or bone pathology (cysts and tumours), absence of all premolars and molars in the lower jaw, and edentulous patients were also excluded.

BMD measurement
---------------

Scans of the mandible were performed and BMD (g/cm^2^) was calculated using the DXA device (GE Lunar DPX-NT, LUNAR Corp., Madison, WI, USA). Scanning procedures and BMD measurements were performed on the body of the mandible as previously described ([Figure 1](#f1-tcrm-11-1587){ref-type="fig"}).[@b19-tcrm-11-1587]--[@b21-tcrm-11-1587] The BMD of the mandible was measured and analyzed by a single-blind operator.

Statistical analysis
--------------------

Statistical analysis was performed with the Statistical Package for the Social Science Program (version 20.0, IBM Corporation, Armonk, NY, USA). The normality and homogeneity of the sample were confirmed by the Shapiro--Wilk tests, after which the one-way analysis of variance/Tukey honest significant difference tests were used to determine any intergroup differences. Differences in individual parameters between the whole BD group and the control group were tested using the Student's *t*-test. A value of *P*\<0.05 was considered statistically significant.

Results
=======

Evaluation was made of the data of 75 patients, comprising 36 females (48%) and 39 males (52%), with a mean age of 37.56±8.2 years (range: 22--63 years) ([Tables 1](#t1-tcrm-11-1587){ref-type="table"} and [2](#t2-tcrm-11-1587){ref-type="table"}). There was only a significant difference between group 4 and the other groups regarding age (*P*\<0.05) (47.27±7.5 years \[range: 34--63 years\]) ([Table 1](#t1-tcrm-11-1587){ref-type="table"}).

The characteristics of the study participants are shown (mean ± SD) in [Tables 1](#t1-tcrm-11-1587){ref-type="table"} and [2](#t2-tcrm-11-1587){ref-type="table"}. There was no statistically significant difference between the study and control groups with respect to sex and body mass index (BMI) variables (*P*\>0.05).

There was found to be no statistically significant difference between the three study groups and the control group in respect of the mandibular body BMD (*P*\>0.05). However, the mandibular body BMD was highest in the control group patients (1.294±0.21 g/cm^2^) and gradually reduced through the study subgroups (group 2: 1.251±0.22 g/cm^2^, group 3: 1.249±0.20 g/cm^2^, group 4: 1.147±0.24 g/cm^2^) ([Table 1](#t1-tcrm-11-1587){ref-type="table"}). No statistically significant differences were determined (*P*\>0.05) ([Table 2](#t2-tcrm-11-1587){ref-type="table"}).

Discussion
==========

This study with a relatively small sample size group examined the comparison of mandibular BMD between BD patients and healthy individuals and showed that although there was no statistically significant difference, bone loss can occur in BD patients. To the best of our knowledge, this is the first study in the literature to investigate mandibular body BMD in BD patients.

The findings of the study showed the mean mandibular body BMD value of 1.294±0.21 g/cm^2^ in the control group and 1.247±0.22 g/cm^2^ in all the participants in our study which is similar to the findings of Buyukkaplan et al[@b20-tcrm-11-1587] (1.10±0.31 g/cm^2^), Pluskiewicz et al[@b22-tcrm-11-1587] (1.221±0.3 g/cm^2^), Devlin and Horner[@b23-tcrm-11-1587] (1.15±0.26 g/cm^2^), Drage et al[@b24-tcrm-11-1587] (1.38±0.39 g/cm^2^), and Esfahanizadeh et al[@b21-tcrm-11-1587] (1.386±0.320 g/cm^2^). Different BMD values in studies may be associated with "region of interest (ROI)" or dentulous/edentulous patients.

OP is a systemic skeletal disorder characterized by bone loss and structural deterioration of bone tissue, which may lead to bone fragility and an increased susceptibility to fractures. Recently, there have been many studies on OP in several rheumatological and chronic inflammatory disorders such as BD, RA, ankylosing spondylitis, FMF, and SLE.[@b7-tcrm-11-1587]--[@b9-tcrm-11-1587] In these diseases, multiple factors may be responsible for bone mass reduction, especially the inflammatory process and the treatment drugs.

BD is a polysymptomatic and recurrent systemic vasculitis with a chronic course and unknown cause. In the inflammatory process, proinflammatory cytokines, such as tumor necrosis factor-α, interleukin- (IL-) 1β, IL-6, and IL-17 can upregulate and may cause increased bone resorption and decreased BMD.[@b3-tcrm-11-1587],[@b25-tcrm-11-1587] According to the degree of the disease, various drugs are used to control the signs and symptoms of BD. The main goal of drug therapy is to reduce symptoms, reduce inflammation, control the immune system, maintain remission, and improve the patient's quality of life. Although there has been no consensus on a treatment program, many medications have been used to reduce inflammation or modify the immune system, including colchicine, corticosteroids, antitumor necrosis factor agents (infliximab and etanercept), thalidomide, and cyclosporine.[@b1-tcrm-11-1587] Colchicine and corticosteroids are suspected to reduce BMD.

Due to the inflammatory processes and long-term drug use, BMD may be affected by the disease duration and activity. Laan et al[@b12-tcrm-11-1587] reported that BMD can be reduced with a long-term disease duration in patients with RA. However, Biçer et al[@b10-tcrm-11-1587] reported no association between disease duration and BMD. In the present study, a reduction in BMD values was determined in patients with long-term disease duration, although it was not statistically significant.

In oral and maxillofacial surgery, decreased BMD can affect the decision-making for placement, success/survival and osseointegration of dental implants, success of bone regeneration therapies (osteotomies, bone augmentations, guided-bone-regeneration, and bone grafting), and bone loss in periodontitis.[@b26-tcrm-11-1587]--[@b29-tcrm-11-1587] Studies have shown a positive correlation between BMD and bone quality.[@b30-tcrm-11-1587]--[@b32-tcrm-11-1587] Pommer et al[@b33-tcrm-11-1587] found that radiographic bone density significantly impacted implant stability values and local jawbone density was reported to be the major determinant of primary implant stability in the maxillary sinus floor of shortened height. Türkyılmaz et al[@b34-tcrm-11-1587] reported significant correlations between bone quality and implant stability parameters. Therefore, all diseases and conditions that affect BMD are closely related to oral surgery.

Esfahanizadeh et al[@b21-tcrm-11-1587] reported that since there was a significant correlation between the densities of skeletal and jaw bones and the presence of OP or osteopenia, the maxilla and mandible may reflect the same situation. Pluskiewicz et al[@b22-tcrm-11-1587] also reported that mandibular BMD may be an appropriate measurement site for assessment of OP. However, Gulsahi et al[@b35-tcrm-11-1587] suggested that the BMD of the jaws was not correlated with femoral BMD. It was explained that these different results may have arisen from different sizes of ROI selection and the measurement of specific areas (anterior, premolar and molar regions of maxilla and mandible).

Mandibular BMD can be measured in the body, symphysis, and ramus regions. Horner et al[@b36-tcrm-11-1587] suggested that the mandibular body has greater sensitivity and specificity compared with the ramus and symphysis regions in the detection of OP. Therefore, in the present study, the BMD measurements were performed on the body of the mandible.

DXA is the gold standard for measurement of BMD. Due to its rapid, highly reproducible, very precise, low cost, and radiation dosage properties, DXA is the most widely accepted and utilized technology.[@b37-tcrm-11-1587]

Limitations
===========

Limitations of the present study include the small sample size and that there was no information about drug dosages and types and dentolous/edentulous patients. Further studies are needed of larger study groups.

Conclusion
==========

The results of this study have shown that long-term disease duration may cause decreased mandibular BMD and BD patients had lower BMD than control group, although it was not statistically important.
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###### 

Characteristics of patients (all groups) according to age, BMI, and BMD

  Characteristics                                           Age                  BMI (kg/m^2^)            BMD (g/cm^2^)
  --------------------------------------------------------- -------------------- ------------------------ -------------------------
  Group 1 (controls)                                        35.5±6.8 (22--45)    28.20±4.7 (19.3--37.5)   1.294±0.21 (0.86--1.71)
  Group 2 (0--5 years)                                      33.67±6.5 (23--44)   27.49±5.7 (17.1--39.3)   1.251±0.22 (0.83--1.55)
  Group 3 (5--10 years)                                     35.87±6.0 (27--45)   24.90±3.5 (19.4--32.5)   1.249±0.20 (0.83--1.52)
  Group 4 (+10 years)                                       47.27±7.5 (34--63)   26.85±4.2 (21.1--34.4)   1.147±0.24 (0.79--1.57)
  Total                                                     37.56±8.2 (22--63)   27.12±4.7 (17.1--39.3)   1.247±0.22 (0.79--1.71)
  *P*-values[\*](#tfn1-tcrm-11-1587){ref-type="table-fn"}   0.000                0.167                    0.228

**Notes:**

One-way ANOVA test, Tukey HSD. Data are represented as mean ± standard deviation.

**Abbreviations:** ANOVA, analysis of variance; BMD, bone mineral density; BMI, body mass index; HSD, honest significant difference.

###### 

Characteristics of patients (all Behçet's patients and controls) according to age, BMI, and BMD

  Characteristics                                          Age          BMI (kg/m^2^)   BMD (g/cm^2^)
  -------------------------------------------------------- ------------ --------------- ---------------
  All Behçet's patients                                    38.93±8.93   26.4±4.6        1.216±0.22
  Controls                                                 35.50±6.80   28.2±4.7        1.294±0.21
  Total                                                    37.56±8.2    27.12±4.7       1.247±0.22
  *P*-value[\*](#tfn3-tcrm-11-1587){ref-type="table-fn"}   0.078        0.108           0.139

**Note:**

Student's *t*-test.

**Abbreviations:** BMD, bone mineral density; BMI, body mass index.
